K. Gowen

发表

Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI‐1)–Deficient Carcinomas of the Urinary System

J. Ross, N. Agarwal, V. Miller, 2017, Clinical genitourinary cancer.

Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP).

James X. Sun, R. Yelensky, V. Miller, 2016 .

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

James X. Sun, J. Ross, V. Miller, 2016 .

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

P. Stephens, S. Ou, Siraj M. Ali, 2016, JAMA oncology.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

A. Drilon, F. Nicolantonio, A. Bardelli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

D. Costa, Siraj M. Ali, K. Gowen, 2017, Lung cancer.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

James X. Sun, V. Miller, G. Frampton, 2018, Journal of gastrointestinal oncology.

Inactivation of Capicua drives cancer metastasis

S. Asthana, Matan Hofree, V. Miller, 2016, Nature Genetics.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

S. Ou, V. Miller, Siraj M. Ali, 2017, The oncologist.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

James X. Sun, J. Gregg, P. Hegde, 2019, The Journal of molecular diagnostics : JMD.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

V. Miller, Siraj M. Ali, C. Lovly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Siraj M. Ali, K. Gowen, J. Elvin, 2017, Gynecologic oncology reports.

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

P. Stephens, V. Miller, F. Meric-Bernstam, 2016, Oncology.

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

S. Ou, Siraj M. Ali, K. Gowen, 2016, Lung cancer.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

P. Stephens, M. Erlander, S. Ou, 2016, Cancer discovery.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

James X. Sun, R. Yelensky, V. Miller, 2016 .

Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy.

P. Stephens, Runjun D. Kumar, R. Bose, 2017, JCO precision oncology.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)

James X. Sun, P. Stephens, S. Ou, 2017 .

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

S. Ou, V. Miller, Siraj M. Ali, 2018, Lung cancer.